New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 4, 2012
06:38 EDTJAZZCorrection: Jazz Pharmaceuticals initiates Erwinaze trial, says Brean Capital
Jazz announced initiated its new clinical trial for Erwinaze with will evaluate intravenous administration in patients with ALL as an alternative to intramuscular injection. Brean Murray maintains its estimates but believes there could be upside to its 2014 forecast. Shares are Buy rated with an $81 price target.
News For JAZZ From The Last 14 Days
Check below for free stories on JAZZ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
11:51 EDTJAZZOECD looks to close tax loopholes with new proposals
Subscribe for More Information
September 8, 2014
08:17 EDTJAZZJazz Pharmaceuticals executing on all cylinders, says Stifel
Following management meetings, Stifel reiterates its Buy rating and $195 price target on Jazz Pharmaceuticals given growth opportunities and sustainability of its current portfolio. The firm agrees with the Xyrem franchise expansion strategies through new patient capture near-term, and longer-term, the addition of complementary wakefulness products.
07:21 EDTJAZZJazz looks more attractive for Allergan than Salix, says Wells Fargo
Subscribe for More Information
September 5, 2014
11:40 EDTJAZZJazz Pharmaceuticals calls active on renewed takeover speculation
Subscribe for More Information
11:00 EDTJAZZRumor: Jazz Pharmaceuticals strength attributed to renewed takeover speculation
Subscribe for More Information
September 3, 2014
07:47 EDTJAZZJazz Pharmaceuticals management to meet with Deutsche Bank
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use